Abstract
We report the results of allogeneic bone marrow transplantation in 26 female and 37 male patients with beta-thalassaemia major (age range: 2-17 years), performed at Namazi Hospital over the period 1992-99. In all cases, standard conditioning and immunosuppressive regimens were employed. Currently, 50 patients remain thalassaemia-free, 9 of whom have developed chronic graft-versus-host disease. There were 8 deaths among the 13 unsuccessful transplant cases: 4 due to acute uncontrollable graft-versus-host disease, and 4 to non-transplant-related causes such as hypoglycaemia, hypersensitivity reactions and advanced disease. We conclude that allogeneic bone marrow transplantation is an effective therapy for the treatment of beta-thalassaemia major, particularly for patients classified as classes I and II.
MeSH terms
-
Acute Disease
-
Adolescent
-
Anti-Inflammatory Agents / therapeutic use
-
Bone Marrow Transplantation* / adverse effects
-
Bone Marrow Transplantation* / immunology
-
Bone Marrow Transplantation* / methods
-
Bone Marrow Transplantation* / mortality
-
Child
-
Child, Preschool
-
Chronic Disease
-
Female
-
Graft Rejection / epidemiology
-
Graft Rejection / etiology
-
Graft vs Host Disease / epidemiology
-
Graft vs Host Disease / etiology
-
Humans
-
Hypoglycemia / epidemiology
-
Hypoglycemia / etiology
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunosuppression Therapy / methods
-
Iran / epidemiology
-
Male
-
Patient Selection
-
Prednisolone / therapeutic use
-
Sepsis / epidemiology
-
Sepsis / etiology
-
Severity of Illness Index
-
Survival Rate
-
Transplantation Conditioning / methods
-
Treatment Outcome
-
beta-Thalassemia / classification
-
beta-Thalassemia / immunology
-
beta-Thalassemia / therapy*
Substances
-
Anti-Inflammatory Agents
-
Immunoglobulins, Intravenous
-
Prednisolone